The Glitazones: Proceed with Caution

Overview

Journal West J Med

Specialty General Medicine

Date 2000 Jul 21

PMID 10903299

Citations 4

Authors

D Krische

Affiliations

Soon will be listed here.

Citing Articles

A generative adversarial network model alternative to animal studies for clinical pathology assessment.

Chen X, Roberts R, Liu Z, Tong W Nat Commun. 2023; 14(1):7141.

PMID: 37932302 PMC: 10628291. DOI: 10.1038/s41467-023-42933-9.

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.

Xu J, Rajaratnam R Cardiovasc Diabetol. 2017; 16(1):18.

PMID: 28148253 PMC: 5288947. DOI: 10.1186/s12933-017-0499-5.

Inflammatory responses in the atria: should they stay or should they go?.

Duffy H Heart Rhythm. 2010; 8(2):286-7.

PMID: 21056699 PMC: 3058228. DOI: 10.1016/j.hrthm.2010.11.006.

Hepatotoxicity with thiazolidinediones: is it a class effect?.

Scheen A Drug Saf. 2001; 24(12):873-88.

PMID: 11735645 DOI: 10.2165/00002018-200124120-00002.

References

Yu J, Kruszynska Y, Mulford M, Olefsky J . A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 1999; 48(12):2414-21. DOI: 10.2337/diabetes.48.12.2414. View

Forman L, Simmons D, Diamond R . Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000; 132(2):118-21. DOI: 10.7326/0003-4819-132-2-200001180-00005. View

Valve R, Sivenius K, Miettinen R, Pihlajamaki J, Rissanen A, Deeb S . Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab. 1999; 84(10):3708-12. DOI: 10.1210/jcem.84.10.6061. View

Kawai T, Takei I, Oguma Y, Ohashi N, Tokui M, Oguchi S . Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism. 1999; 48(9):1102-7. DOI: 10.1016/s0026-0495(99)90122-1. View

Hirsch I, Kelly J, Cooper S . Pulmonary edema associated with troglitazone therapy. Arch Intern Med. 1999; 159(15):1811. DOI: 10.1001/archinte.159.15.1811. View

DeFronzo R . Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999; 131(4):281-303. DOI: 10.7326/0003-4819-131-4-199908170-00008. View

Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N . Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 1999; 22(6):908-12. DOI: 10.2337/diacare.22.6.908. View

Jha R . Thiazolidinediones--the new insulin enhancers. Clin Exp Hypertens. 1999; 21(1-2):157-66. DOI: 10.3109/10641969909068658. View

Subramaniam S . The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders. Clin Exp Hypertens. 1999; 21(1-2):121-36. DOI: 10.3109/10641969909068655. View

10.

Herrine S, Choudhary C . Severe hepatotoxicity associated with troglitazone. Ann Intern Med. 1999; 130(2):163-4. DOI: 10.7326/0003-4819-130-2-199901190-00021. View

11.

Vella A, de Groen P, Dinneen S . Fatal hepatotoxicity associated with troglitazone. Ann Intern Med. 1998; 129(12):1080. DOI: 10.7326/0003-4819-129-12-199812150-00032. View

12.

Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H . An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998; 21(12):2140-3. DOI: 10.2337/diacare.21.12.2140. View

13.

Fonseca V, Valiquett T, Huang S, Ghazzi M, Whitcomb R . Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab. 1998; 83(9):3169-76. DOI: 10.1210/jcem.83.9.5123. View

14.

Horton E, Whitehouse F, Ghazzi M, VENABLE T, Whitcomb R . Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998; 21(9):1462-9. DOI: 10.2337/diacare.21.9.1462. View

15.

Arjomand H, Kemp D, Mittal M . Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000; 132(2):121-4. DOI: 10.7326/0003-4819-132-2-200001180-00006. View

16.

Inoue K, Sano H . Troglitazone-induced pulmonary edema. Arch Intern Med. 2000; 160(6):871-2. DOI: 10.1001/archinte.160.6.871. View

17.

Iwamoto Y, Kuzuya T, Matsuda A, Awata T, Kumakura S, Inooka G . Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991; 14(11):1083-6. DOI: 10.2337/diacare.14.11.1083. View

18.

Suter S, Nolan J, Wallace P, Gumbiner B, Olefsky J . Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 1992; 15(2):193-203. DOI: 10.2337/diacare.15.2.193. View

19.

Nolan J, Ludvik B, Beerdsen P, Joyce M, Olefsky J . Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994; 331(18):1188-93. DOI: 10.1056/NEJM199411033311803. View

20.

Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N . Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med. 1994; 11(7):685-91. DOI: 10.1111/j.1464-5491.1994.tb00333.x. View